Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes - Rosenstock, Julio; Aggarwal, Naresh; Polidori, David; Zhao, Yue; Arbit, Deborah; Usiskin, Keith; Capuano, George; Canovatchel, William (Diabetes care, 2012)
Keywords: administration & dosage; Adolescent; Adult; Aged; Biological and medical sciences; blood; blood glucose; Blood Glucose - drug effects; Blood Glucose - metabolism; Body weight; Canagliflozin; chemically induced; Dextrose; Diabetes; Diabetes Mellitus, Type 2; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - drug therapy; Diabetes therapy; Diabetes. Impaired glucose tolerance; Dose-Response Relationship, Drug; Double-Blind Method; drug effects; drug therapy; Drug Therapy, Combination; Endocrine pancreas. Apud cells (diseases); Endocrinopathies; Etiopathogenesis. Screening. Investigations. Target tissue resistance; fasting; Female; females; Glucose; Glucosides; Glucosides - administration & dosage; Glucosides - pharmacology; glycemic control; Humans; hypoglycemia; Hypoglycemia - blood; Hypoglycemia - chemically induced; Hypoglycemic Agents; Hypoglycemic Agents - administration & dosage; Hypoglycemic Agents - pharmacology; Male; Medical sciences; Metabolic diseases; metabolism; metformin; Metformin - administration & dosage; Metformin - pharmacology; Middle Aged; Miscellaneous; noninsulin-dependent diabetes mellitus; Original Research; pharmacology; Plasma; Public health. Hygiene; Public health. Hygiene-occupational medicine; Sodium; Sodium-Glucose Transporter 2 - antagonists & inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Statistical methods; Thiophenes; Thiophenes - administration & dosage; Thiophenes - pharmacology; Treatment Outcome; Type 2 diabetes; urinary tract diseases; weight loss; Weight Loss - drug effects; Young Adult; Endocrinopathy; Type 2 diabetes; Human; Nutrition; Metabolic diseases; Glucose; Hypoglycemic agent; Biguanides; Sodium; Inhibitor; Metformin; Dose; Endocrinology